Tethys Investments
Tethys Investments is a private equity firm established in 2017 and based in Boston, Massachusetts. The firm specializes in lower-middle-market investments, focusing on growth and distressed assets in Eurasia. Tethys emphasizes regional and country specialization, industry expertise, and rigorous due diligence, combining quantitative analysis with field-intensive qualitative assessments. The firm selectively invests in sectors such as energy, transportation, financial services, agriculture, manufacturing, IT services, and hospitality. Tethys aims to identify investment opportunities that lead to the development of stronger companies, prioritizing social responsibility and long-term returns. Additionally, when favorable exit options are identified within a 5-10 year timeframe, Tethys is open to investing in greenfield projects.
Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
Private Equity Round in 2019
M2I Life Sciences is a French company that focuses on custom synthesis and formulation of specialized products in healthcare, veterinary applications, and agricultural biocontrol. It is particularly noted for its expertise in developing pheromones that offer eco-friendly alternatives to chemical insecticides, thereby supporting the ecological transition in agriculture. The company aims to serve as a comprehensive partner for clients, providing services from initial specifications to regulatory approvals, such as Drug Master Files and Marketing Authorizations. M2I operates a research and development center along with a cGMP manufacturing facility, allowing it to efficiently redesign synthetic routes and industrial processes for complex molecules, thereby catering to the diverse needs of its clients in the fields of generics, crop protection, and organic electronics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.